STOCK TITAN
  1. Home
  2. Sec-filings
  3. BBNX
  4. [Form 4] Beta Bionics, Inc. Insider Trading Activity

Beta Bionics (BBNX) director awarded 16,965 restricted stock units

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

CARNEY SEAN reported acquisition or exercise transactions in this Form 4 filing.

Beta Bionics, Inc. director Sean Carney received a grant of 16,965 shares of common stock as a restricted stock unit award under the company’s 2025 Equity Incentive Plan. The award was recorded at a price of $0.00 per share, bringing his direct holdings to 32,209 shares after the grant.

Positive

  • None.

Negative

  • None.
Insider CARNEY SEAN
Role null
Type Security Shares Price Value
Grant/Award Common Stock 16,965 $0.00 --
Holdings After Transaction: Common Stock — 32,209 shares (Direct, null)
Footnotes (1)
  1. [object Object]
RSU grant size 16,965 shares Restricted stock unit award on May 21, 2026
Price per share $0.00 per share Stated value for the RSU grant
Total holdings after grant 32,209 shares Sean Carney direct common stock ownership post-transaction
Transaction code Code A Grant, award, or other acquisition of common stock
Transaction direction Acquire Classified as grant/award acquisition in Form 4 data
restricted stock unit financial
"Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
2025 Equity Incentive Plan financial
"Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan."
Form 4 regulatory
"After the reported transaction, Sean Carney directly holds 32,209 shares of Beta Bionics common stock as reflected in the Form 4 filing."
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
Grant, award, or other acquisition financial
"Transaction code A is described as Grant, award, or other acquisition."
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
CARNEY SEAN
(Last)(First)(Middle)
C/O BETA BIONICS, INC.
11 HUGHES
(Street)
IRVINE CALIFORNIA 92618
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/21/2026A16,965(1)A$032,209D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan.
/s/ Stephen Feider, Attorney-in-Fact05/26/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Beta Bionics (BBNX) report for Sean Carney?

Beta Bionics reported that director Sean Carney received a grant of 16,965 shares of common stock. The award was structured as restricted stock units under the 2025 Equity Incentive Plan and increased his direct holdings to 32,209 shares following the transaction.

Was the Beta Bionics (BBNX) insider transaction a market purchase or a grant?

The transaction was a grant, not a market purchase. Sean Carney acquired 16,965 shares at $0.00 per share as a restricted stock unit award under Beta Bionics’ 2025 Equity Incentive Plan, reflecting compensation rather than an open-market buy or sell decision.

How many Beta Bionics (BBNX) shares does Sean Carney hold after this Form 4?

After the reported transaction, Sean Carney directly holds 32,209 shares of Beta Bionics common stock. This total includes the 16,965 restricted stock units granted to him on May 21, 2026 under the company’s 2025 Equity Incentive Plan as reflected in the Form 4 filing.

What is the size of the restricted stock unit award reported by Beta Bionics (BBNX)?

The restricted stock unit award consists of 16,965 shares of Beta Bionics common stock. These RSUs were granted at a stated price of $0.00 per share as equity compensation to director Sean Carney under the company’s 2025 Equity Incentive Plan.

What plan governs the recent restricted stock grant at Beta Bionics (BBNX)?

The grant is governed by Beta Bionics’ 2025 Equity Incentive Plan. Under this plan, director Sean Carney received 16,965 restricted stock units, which are reported as common stock in the Form 4 and increased his direct ownership to 32,209 shares after the award.